Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nal-IRI/5-FU/LV + Benmelstobart + Anlotinib ± SBRT in Metastatic Pancreatic Cancer
NCT06662006Phase 2Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of benmelstobart and anlotinib in pancreatic cancer (PC) (2 cohorts), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Objective Response Rate. Started Mar 2024; status: recruiting.
02
Drugs
benmelstobartanlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06662006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662006.